Great article in
@statnews by
@damiangarde today covering schism in the biotech industry over the rise of Chinese biotech industry - notably no one will go on record but meš
The US can easily stop the Chinese biotech industry whenever it chooses as the US consumer is responsible for 70% (!!!) of the drug industry profits. Thus the US gets to set the rules.
It is a mistake to outsource this industry -- very simply: the technology of genetic engineering is a matter of national security and democracies should lead it. We would not feel good if the US wasn't leading AI today and trust me we will feel even worse if we are behind in genetic engineering in the future as the tech improves.
If you talk to people privately in biotech they will say it's a Prisoner's dilemma where they wish the rules would change. If the rules stay as they are then to stay competitive venture capitalists need to move their $ to China and pharma companies need to buy their drug assets from Chinese startups instead of from startups in Kendall Square or South San Francisco (the current US hubs for drug discovery).
To fix this we should take two approaches:
(1) Offensive - make US biotech industry more competitive!
* Reform phase 1 clinical trails in US to be as fast as China and Australia -- this is in progress now at
@US_FDA .
@DrSynbio congressional testimony on this was very helpful. (link below).
* Replace manual laboratories with autonomous robotic laboratories via programs like NSF Cloud Labs program and
@SenToddYoung 's Cloud Lab BillĀ so US scientists can compete with lower-cost scientific labor in China. Yes,
@ginkgo is the leader in making this tech. Efforts from
@WHOSTP44.
@dariogila,
@mkratsios47,
@sriramk with the WH Genesis Mission are a big help here.
* Fix our approach to biotech patents -- it is very easy for Chinese startups to fast-follow US companies that have scientific breakthroughs by easily working around patents,
@john_evans3 has led in thinking here.
(2) Defensive - slowĀ the rise of the biotechnology industry in China
* USG should add biotechnology to the COINS Act list of strategic technologies alongside AI, Quantum, Semiconductors, and Drones to prevent US investment from speeding Chinese development.
* Other tools can be used in the future to easily penalize drug assets that originate from startups in China -- can do via regulatory pathway or via Medicare reimbursement.
Genetic engineering is the most important technology to the future of humanity. Democracies should not give up on it! Let's fight for it!